Century Therapeutics (IPSC) Capital Expenditures (2020 - 2026)

Century Therapeutics (IPSC) has 7 years of Capital Expenditures data on file, last reported at $584000.0 in Q1 2026.

• On a quarterly basis, Capital Expenditures rose 22.95% year-over-year to $584000.0 in Q1 2026; TTM through Mar 2026 was $957000.0, a 57.64% decrease from a year earlier, with the FY2025 full-year figure at $848000.0, up 450.65% from the prior year.
• Capital Expenditures for Q1 2026 stood at $584000.0, up from -$139000.0 in the prior quarter.
• Over the last five years, Capital Expenditures for IPSC reached as high as $10.5 million in Q2 2022 and fell as low as -$21.7 million in Q4 2022.
• Historically, Capital Expenditures has averaged $1.2 million across 5 years, with a median of $584000.0 in 2026.
• On a YoY basis, Capital Expenditures climbed as much as 303.86% in 2022 and fell as far as 241.99% in 2022.
• Year by year, Capital Expenditures stood at -$21.7 million in 2022, then jumped by 104.52% to $980000.0 in 2023, then plunged by 72.96% to $265000.0 in 2024, then plunged by 152.45% to -$139000.0 in 2025, then soared by 520.14% to $584000.0 in 2026.
• Per Business Quant data, the three most recent Capital Expenditures figures were $584000.0 in Q1 2026, -$139000.0 in Q4 2025, and $195000.0 in Q3 2025.